No-Fault Compensation for Vaccine Injury — The Other Side of Equitable Access to Covid-19 Vaccines
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
No-Fault Compensation for Vaccine Injury Pharmaceutical companies won’t distribute Covid-19 vaccines to lower-income countries without liability protection. To efficiently handle claims, the COVAX ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the WHO Working Group also concluded that no-fault compensation schemes should be implemented to give people experiencing a serious vaccine adverse event (vaccine injury) access to a remedy without needing to resort to litigation (World Health Organization 2022; Halabi, Heinrich, and Omer 2020).”
From Ethical Principles in Legal Context: Vaccine Mandates During the COVID-19 Pandemic in Australia (2026) · cites this paper as Halabi, Heinrich, and Omer 2020
Citations
Cites
Mungwira, R. G., Guillard, C., Saldaña, A., Okabe, N., Petousis-Harris, H., Agbenu, E., Rodewald, L., & Zuber, P. L. F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233334 · Cited by 68
Becker, M., Dörfler, T., & Gehring, T. (2018) · Regulation & Governance · doi:10.1111/rego.12195 · Cited by 6
Research works printed but not linked: 1
- Mello MM, 2008, Bioethics, 22, 32
Cited by
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00306-8 · Cited by 1,288
Enhancing public trust in COVID-19 vaccination: The role of governments
(2021) · OECD Policy Responses to Coronavirus (COVID-19) · doi:10.1787/eae0ec5a-en · Cited by 297
Boro, E., & Stoll, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.928065 · Cited by 100
“(71) 3 December, 2020 Commentary N/A 5 (Expert Opinion) Market forces; availability International & regional LMICs”
BackgroundPanneer, S., Kantamaneni, K., Palaniswamy, U., Bhat, L. D., Pushparaj, R. R. B., Nayar, K. R., Manuel, H. S., Flower, F. X. L. L., & Rice, L. (2022) · Healthcare · doi:10.3390/healthcare10050770 · Cited by 93
“Culturally tailored health communication measures [86], community engagement [87] and a robust pharmacovigilance system [88] are important strategies for addressing vaccine hesitancy.”
BackgroundEthics of ICU triage during COVID-19
Vinay, R., Baumann, H., & Biller‐Andorno, N. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldab009 · Cited by 76
Assessment of COVID-19 vaccine hesitancy among Zimbabweans: A rapid national survey
Mundagowa, P. T., Tozivepi, S. N., Chiyaka, E. T., Mukora-Mutseyekwa, F., & Makurumidze, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266724 · Cited by 56
Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation
Löffler, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663280 · Cited by 48
D’Errico, S., Zanon, M., Concato, M., Peruch, M., Scopetti, M., Frati, P., & Fineschi, V. (2021) · Vaccines · doi:10.3390/vaccines9101116 · Cited by 24
“The debate around the importance to compensate for vaccine-related injuries has taken on more pertinence as COVID-19 vaccine programmes are rolled out worldwide [20].”
BackgroundGorodensky, A., & Kohler, J. C. (2022) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-022-00442-y · Cited by 21
“To reap compensation for vaccine-related injuries through no-fault compensation schemes, however, patients do not need to prove fault; in some jurisdictions such as the United States, patients who make a claim to a compensation scheme waive their right to bring a civil case against the vaccine manufacturer [32, 80, 81…”
BackgroundCrum, T., Mooney, K., & Tiwari, B. R. (2021) · F1000Research · doi:10.12688/f1000research.51160.1 · Cited by 20
Barranco, R., Rocca, G., Molinelli, A., & Ventura, F. (2021) · Healthcare · doi:10.3390/healthcare9091163 · Cited by 20
“Excluding countries that are unable to provide compensation would have deprived many people of vaccine protection and would not have allowed them to fight SARS-CoV-2 [23].”
BackgroundInfluentialBusiness-as-Usual will not Deliver the COVID-19 Vaccines We Need
Torreele, E. (2020) · Development · doi:10.1057/s41301-020-00261-1 · Cited by 12
Stages in COVID-19 vaccine development: The Nemesis, the Hubris and the Elpis
Nikhra, V. (2020) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001028 · Cited by 12
“In the current situation the same kind of immunity is being claimed by the vaccine manufacturers [36].”
BackgroundScience as Experience: A Deweyan Model of Science Communication
Halpern, M. K., & Elliott, K. C. (2022) · Perspectives on Science · doi:10.1162/posc_a_00398 · Cited by 13
No-Fault Compensation and Anti-COVID-19 Compulsory Vaccination: The Italian Context in a Broad View
Frati, P., Fazio, N. D., Russa, R. L., Santoro, P., Delogu, G., & Fineschi, V. (2022) · Vaccines · doi:10.3390/vaccines10050635 · Cited by 9
“The COVAX No-Fault Compensation Program is the first international vaccine injury compensation mechanism intended for Advance Market Commitment (AMC) Eligible Economies [42,43].”
BackgroundWeitzman, E. R., Sherman, A. C., & Levy, O. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.695807 · Cited by 10
“Similarly, the process by which injury is asserted and compensated and the mechanisms by which accountability is established and liability protected against (no-fault compensation) were perceived as unclear and suspect (12).”
BackgroundVaccination for COVID-19 control and considerations for Australia
MacIntyre, C. R. (2021) · Microbiology Australia · doi:10.1071/ma21009 · Cited by 7
Hassan, F., Abinader, L. G., & Kavanagh, M. M. (2025) · Global Public Health · doi:10.1080/17441692.2025.2537688 · Cited by 9
“For most countries, offering pharmaceutical companies indemnity or complete immunity from lawsuits if their products cause harm is constitutionally or financially impossible (Halabi et al., 2020).”
Farshidfar, N., Jafarpour, D., Hamedani, S., Dziedzic, A. M., & Tanasiewicz, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102116 · Cited by 7
“As of 10th March 2021, there were more than 200 vaccines in pre-clinical and clinical development [50], including 21 in phase three trials, six in the early/limited use phase, and six approved for full use [51].”
BackgroundA review of China’s compensation program for adverse reactions following immunization
Yingxiong, W. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1211976 · Cited by 7
“Although the existing no-fault VICPs in 25 countries do not directly cover injuries related to COVID-19 vaccines (16), some countries have activated their emergency compensation programs.”
BackgroundTan, L. J., Koh, C. P., Lai, S. K., Poh, W. C., Othman, M. S., & Hussin, H. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111469 · Cited by 6
“Unfortunately, due to the limitation of time, guideline and procedure in the postmortem investigation during the pandemic, bias in the justification of the causal association between vaccination and death remained unsolved [2].”
BackgroundSideri, K. (2024) · Journal of Responsible Innovation · doi:10.1080/23299460.2024.2425121 · Cited by 7
Anderson, M. R., Hardy, E. J., & Battle, C. L. (2022) · Women s Health Issues · doi:10.1016/j.whi.2022.04.001 · Cited by 5
Halabi, S., Arora, N., Durran, A., Qian, Q., Ummer, S., Ginsbach, K., & Aneja, K. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2620849 · Cited by 4
Self-citationUnderstanding the Barriers to Equitable Access to Vaccines: An Analysis of COVAX
Upton, H. (2024) · Global Health Cases · doi:10.1079/globalhealthcases.2024.0003 · Cited by 4
Legal frameworks for outbreak response
Liu, E., Kirpalani, D., & Berman, A. (2024) · NUS Press eBooks · doi:10.56159/emergencies-4 · Cited by 3
Tecnologias e preços no mercado de medicamentos
(2024) · Instituto de Pesquisa Econômica Aplicada (Ipea) eBooks · doi:10.38116/9786556350806 · Cited by 2
Wakabayashi, M., Ezoe, S., Yoneda, M., Katsuma, Y., & Iso, H. (2021) · GHM Open · doi:10.35772/ghmo.2021.01029 · Cited by 2
Mustaffa, N. M., Mokhtar, F. S., Ariff, A. M., Manap, N. A., & Wahid, M. E. A. (2023) · Universiti Malaysia Terengganu Journal of Undergraduate Research · doi:10.46754/umtjur.v5i2.412 · Cited by 2
What is the potential of compensation funds for addressing COVID-related personal injury?
Knetsch, J., & Watts, K. (2023) · The Geneva Papers on Risk and Insurance Issues and Practice · doi:10.1057/s41288-023-00292-y · Cited by 2
“It does not include no-fault compensation frameworks for vaccine damage, which has been considered already in other scholarship (Watts and Popa 2021; Raposo 2021; Halabi et al. 2020).”
BackgroundEthical Principles in Legal Context: Vaccine Mandates During the COVID-19 Pandemic in Australia
Thomasson, A., Williams, J., Drislane, S., & Rizzi, M. (2026) · Journal of Bioethical Inquiry · doi:10.1007/s11673-026-10570-8 · Cited by 1
27 A Global Framework for Research Preparedness and Response
Lurie, N., & Keusch, G. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_40 · Cited by 1
Maya-Díaz, Z., Vargas-Neri, J. L., Carbajal-Rodríguez, L., Negrete-Paz, M. D. S., & Castañeda‐Hernández, G. (2025) · Latin American Journal of Clinical Sciences and Medical Technology · doi:10.34141/ljcs9881000 · Cited by 1
Luik, O.-J., & Kinkar, R. (2025) · Juridica International · doi:10.12697/ji.2025.34.06 · Cited by 1
Xantus, G. Z., Rékassy, B., & Závori, L. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32172 · Cited by 1
Wakabayashi, M., Ezoe, S., Yoneda, M., Katsuma, Y., & Iso, H. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01029 · Cited by 1
“The COVAX No-Fault Compensation Program started in April 2021 to protect the 92 eligible economies (24,25), and the COVAX Facility requested that all participating countries make indemnification and”
Deglobalize Covid-19: the pandemic from an off-center perspective
Barria‐Asenjo, N. A., Žižek, S., Scholten, H., Salas, G., Constanzo, A. Z., Acosta, J. G., Gómez, E., & Muñoz, J. E. U. (2021) · Sociedade e Estado · doi:10.1590/s0102-6992-202136030006 · Cited by 1
Intellectual property barriers to access to COVID-19 health products in South Africa
Vawda, Y. A., Tomlinson, C., Gray, A., London, L., & Paremoer, L. (2022) · South African Health Review · doi:10.61473/001c.75425 · Cited by 1
COVID-19 Vaccine Development and Delivery: The Nemesis, the Hubris, and the Elpis
Nikhra, V. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.32.005276
“In the current situation the same kind of immunity is being claimed by the vaccine manufacturers [28].”
BackgroundWidjaja, G. (2021) · Budapest International Research and Critics Institute (BIRCI-Journal): Humanities and Social Sciences · doi:10.33258/birci.v4i4.3197
(2021) · Microbiology Australia · doi:10.1071/mav42n1
Holovatenko, M. (2022) · Analytical and Comparative Jurisprudence · doi:10.24144/2788-6018.2022.05.8
Economic Policies as Moral Disputes During the COVID-19 Pandemic
Jones, M. (2023) · Springer eBooks · doi:10.1007/978-981-16-9859-0_3-1
COVID-19 Vaccine Development: The Need, the Fast-track, and the Concerns
Nikhra, V. (2021) · Annals of Immunology & Immunotherapy · doi:10.23880/aii-16000130
“In the current situation the same kind of immunity is being claimed by the vaccine manufacturers [27].”
BackgroundAumentar la confianza pública en la vacunación contra el COVID 19: El papel de los gobiernos
OECD (2021) · Medidas políticas clave de la OCDE ante el coronavirus (Covid-19) · doi:10.1787/4e654177-es
32.2 In Focus: Clinical Trial Insurance and Indemnification
Larson, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_49
Economic Policies as Moral Disputes During the COVID-19 Pandemic
Jones, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7802-1_3
O Mercado de vacinas no Brasil
Negri, F. D., Arbix, G., & Pereira, L. D. S. (2024) · Instituto de Pesquisa Econômica Aplicada (Ipea) eBooks · doi:10.38116/9786556350806cap3
Kavanagh, M. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5364128
COVID-19 Policy Playbook II: Legal Recommendations for a Safer, More Equitable Future
(2021) · TUScholarShare (Temple University) · doi:10.34944/dspace/6236 · Cited by 3
Pasqualotto, A. D. S., & Vidaletti, L. P. (2022) · PUCRS Repository (Pontifical Catholic University of Rio Grande do Sul)
Vidaletti, L. P. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Halabi, S., Heinrich, A., & Omer, S. B.
- Affiliations
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-03
- Volume
- 383
- Issue
- 23
- Pages
- e125
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3095406687
- Cited by
- 44
- References
- 2
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 9 · 2021: 19 · 2020: 3
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Social Sciences › Law › Medical Malpractice and Liability Issues
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- no-fault compensation, vaccine injury, COVID-19 vaccines, vaccine equity, pharmaceutical liability, COVAX, vaccine distribution, low-income countries
- MeSH terms
- COVID-19, COVID-19 Vaccines, Humans, Vaccination, Liability, Legal, Compensation and Redress, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.